Weiter zum Inhalt
Toggle navigation
English
English
Favoritenliste (
0
)
(Voll)
Kontakt
Mein Konto
Abmeldung
Mein Konto
Suche
Filter bei nächster Suche beibehalten
topic_facet:"Medical Condition: Multiple Myeloma MedDRA version: 21.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864;Therapeutic area: Diseases [C] - Cancer [C04]"
Erweiterte Suche
Suchverlauf
Struktursuche
Narrative Service
Drug Overviews
Info Guide
/vufind/Search/Results?filter%5B%5D=topic_facet%3A%22Medical+Condition%3A+Multiple+Myeloma+MedDRA+version%3A+21.0Level%3A+LLTClassification+code+10028228Term%3A+Multiple+myelomaSystem+Organ+Class%3A+100000004864%3BTherapeutic+area%3A+Diseases+%5BC%5D+-+Cancer+%5BC04%5D%22&lookfor=%22Recruitment+Status%3A+Authorised-recruitment+may+be+ongoing+or+finished%22&type=Subject&page=5
/vufind/Search/Results?filter%5B%5D=topic_facet%3A%22Medical+Condition%3A+Multiple+Myeloma+MedDRA+version%3A+21.0Level%3A+LLTClassification+code+10028228Term%3A+Multiple+myelomaSystem+Organ+Class%3A+100000004864%3BTherapeutic+area%3A+Diseases+%5BC%5D+-+Cancer+%5BC04%5D%22&lookfor=%22Recruitment+Status%3A+Authorised-recruitment+may+be+ongoing+or+finished%22&type=Subject&page=5
Search /vufind/Search2/Results?filter%5B%5D=topic_facet%3A%22Medical+Condition%3A+Multiple+Myeloma+MedDRA+version%3A+21.0Level%3A+LLTClassification+code+10028228Term%3A+Multiple+myelomaSystem+Organ+Class%3A+100000004864%3BTherapeutic+area%3A+Diseases+%5BC%5D+-+Cancer+%5BC04%5D%22&lookfor=%22Recruitment+Status%3A+Authorised-recruitment+may+be+ongoing+or+finished%22&type=Subject&page=5
PubPharm (152)
41
Treatment of unfit and frail newly diagnosed multiple myeloma patients with ixazomib, daratumumab and low dose dexamethasone (IDd) followed by ixazomib and daratumumab maintenance therapy until progression for a maximum of 2 years in .How effective is this treatment and how well is it tolerated? : Efficacy and tolerability of ixazomib, daratumumab and low dose dexamethasone (IDd) followed by ixazomib and daratumumab maintenance therapy until progression for a maximum of 2 years in unfit and frail newly diagnosed multiple myeloma patients; an open-label phase II trial
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
42
An Open Label Study of JNJ-68284528, Directed Against BCMA in Subjects with Multiple Myeloma : A Phase 2, Multicohort Open-Label Study of JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA in Subjects with Multiple Myeloma
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
43
A study to investigate Isatuximab alone or in combination with CellProtect as maintenance treatment after stem cell transplantation in patients with newly diagnosed multiple myeloma : An open, randomised, controlled phase II trial of CellProtect in combination with Isatuximab antibody versus Isatuximab antibody alone as maintenance treatment in patients with Multiple Myeloma undergoing high dose treatment
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
44
Treatment of unfit and frail newly diagnosed multiple myeloma patients with ixazomib, daratumumab and low dose dexamethasone (IDd) followed by ixazomib and daratumumab maintenance therapy until progression for a maximum of 2 years in .How effective is this treatment and how well is it tolerated? : Efficacy and tolerability of ixazomib, daratumumab and low dose dexamethasone (IDd) followed by ixazomib and daratumumab maintenance therapy until progression for a maximum of 2 years in unfit and frail newly diagnosed multiple myeloma patients; an open-label phase II trial
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
45
An Open Label Study of JNJ-68284528, Directed Against BCMA in Subjects with Multiple Myeloma : A Phase 2, Multicohort Open-Label Study of JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA in Subjects with Multiple Myeloma
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
46
A study to investigate Isatuximab alone or in combination with CellProtect as maintenance treatment after stem cell transplantation in patients with newly diagnosed multiple myeloma : An open, randomised, controlled phase II trial of CellProtect in combination with Isatuximab antibody versus Isatuximab antibody alone as maintenance treatment in patients with Multiple Myeloma undergoing high dose treatment
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
47
A randomized phase III study to compare Bortezomib, Melphalan, Prednisone (VMP) with High Dose Melphalan followed by Bortezomib, Lenalidomide, Dexamethasone (VRD) consolidation and Lenalidomide maintenance in patients with newly diagnosed multiple myeloma : A randomized phase III study to compare Bortezomib, Melphalan, Prednisone (VMP) with High Dose Melphalan followed by Bortezomib, Lenalidomide, Dexamethasone (VRD) consolidation and Lenalidomide maintenance in patients with newly diagnosed multiple myeloma - HOVON 95 MM
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
48
First in Human (FIH) Study of REGN5458 in Patients With Relapsed or Refractory Multiple Myeloma : PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
49
A randomized phase III study to compare Bortezomib, Melphalan, Prednisone (VMP) with High Dose Melphalan followed by Bortezomib, Lenalidomide, Dexamethasone (VRD) consolidation and Lenalidomide maintenance in patients with newly diagnosed multiple myeloma : A randomized phase III study to compare Bortezomib, Melphalan, Prednisone (VMP) with High Dose Melphalan followed by Bortezomib, Lenalidomide, Dexamethasone (VRD) consolidation and Lenalidomide maintenance in patients with newly diagnosed multiple myeloma - HOVON 95 MM
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
50
First in Human (FIH) Study of REGN5458 in Patients With Relapsed or Refractory Multiple Myeloma : PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
[1]
« Vorheriger
1
2
3
4
5
6
7
8
9
10
11
Nächster »
[16]
Filter & Sortierung
Treffer pro Seite
10
20
50
Sortieren
Relevanz
Neueste zuerst
Älteste zuerst
Verfasser
Zeitschriftentitel
Bibliothek
Standort (Printmedien)
Verwandte Substanzen
Verwandte Substanzen werden ermittelt...
Verwandte Erkrankungen/Symptome
Verwandte Erkrankungen/Symptome werden ermittelt...
Verwandte Gene
Verwandte Gene werden ermittelt...
Systematic Reviews
Clinical Studies
Patente
Covid-19/SARS-CoV-2
Exclude Systematic Reviews
Exclude Clinical Studies
Exclude Patents
Ihre gewählten Filter
Filter bei nächster Suche beibehalten
Filter aufheben
Thema: Medical Condition: Multiple Myeloma MedDRA version: 21.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864;Therapeutic area: Diseases [C] - Cancer [C04]
Medienart
152
Aufsätze
152
E-Artikel
152
E-Ressourcen
Zeitschriftentitel
152
WHO International Clinical Trials Registry Plat...
Thema
152
610
Medical Condition: Multiple Myeloma MedDRA vers...
152
Recruitment Status: Authorised-recruitment may ...
152
Study Type: Interventional
92
Phase: Phase 3
56
Phase: Phase 2
2
Phase: Phase 1
2
Phase: Phase 4
Alle anzeigen ...
weniger ...
Erscheinungszeitraum
14
2023
54
2022
46
2021
38
2020
Erscheinungsjahr(e)
Von:
Bis:
Sprache
152
Englisch
Haven't found what you're looking for?
Wird geladen...